MedTrace Logo

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

NCT04669197 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-08-15

No results posted yet for this study

Summary

To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.

Conditions

  • Untreated Resectable Pancreatic Adenocarcinoma
  • Borderline Resectable Pancreatic Adenocarcinoma
  • Locally Advanced Pancreatic Adenocarcinoma

Interventions

DRUG

Paclitaxel protein bound

combination therapy

DRUG

Gemcitabine

combination therapy

DRUG

Cisplatin

combination therapy

DRUG

Hydroxychloroquine

combination therapy

Sponsors & Collaborators

  • HonorHealth Research Institute

    lead OTHER

Principal Investigators

  • Erkut Borazanci, MD · HonorHealth Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2024-02-21
Completion
2025-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04669197 on ClinicalTrials.gov